This convenient new process will allow you to receive all 3 vials in a single delivery, simplifying your treatment plan
Yue L, Gao C, Li J, Chen H, Lee SMY, Luo R, et al
Based on the anticipated Phase 3 timelines, regulatory submissions are unlikely before the mid-to-late 2020s, though this is contingent on trial completion and data review processes
Importantly, whether considering the targeting of the T or B cell in type 1 diabetes, sufficient long-term benefits via systemic cell pool depletion comes with an inherent risk of introducing equally long-term or even irreversible changes to the immune system
doi: 10.1038/s41598-022-16420-y 19 Oncu-OnerTCanS
Human T cell Development, Localization, and function throughout life